A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

NCT04200456 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

33

Enrollment

INDUSTRY

Sponsor class

Stopped Strategic Business Decision; Not a safety decision

Conditions

Primary Immune Thrombocytopenia

Interventions

DRUG: Rozanolixizumab
OTHER: Placebo

Sponsor

UCB Biopharma SRL